NEWSPACE-CAPITAL
NewSpace Capital announces the first closing of its space-focused growth fund at €105M and a €15M lead investment in Cailabs’ series C investment round.
NewSpace Capital is a Luxembourg-based private equity fund dedicated to space-focused technology investments. The firm targets growth-equity opportunities in downstream applications and supply chain segments of the space market. NewSpace Capital has a global investment outlook with its main focus on Europe and the US. The closing was led by a cornerstone investment from Archean Capital Partners, a US fund dedicated to investing in emerging fund managers with specialized sector and operational experience. Other investors include corporates, financial institutions and family offices.
NewSpace Capital is also announcing a €15M investment in Cailabs, a French deep-tech company enabling revolutionary photonic solutions for industrial and communication applications. NewSpace Capital is the lead investor in Cailabs’ €26M series C financing round.
The fund’s other investments to date include ICEYE, which owns and operates the world’s largest constellation of synthetic aperture radar (SAR) satellites, and Kayrros, a climate-tech data analytics company that recently won the Financial Times’ prestigious 2022 Tech Champions Award.
Rob Lazaroff, Co-Portfolio Manager of Archean Capital said, “There are an increasing number of companies reaching the commercial stage in space, many of which are ready for growth stage capital. The NewSpace Capital team has an ideal mix of technical and commercial expertise to identify and select the best space companies, and help them achieve their growth plans.”
“We are very selective in backing new funds and we are willing to wait for the right combination of team, strategy and market opportunity. NewSpace Capital has an amazing network within the space ecosystem that makes them a preferred partner to companies like Cailabs. We are thrilled to support the team as they build NewSpace Capital into the next market leading private equity firm” said Chris Keller, Co-Portfolio Manager of Archean Capital.
“The space ecosystem becomes a backbone for economic and social change. We are a value investor in companies that enable this process with new technologies and capabilities. NewSpace Capital allows its LPs to tap into the growth segment of a €300-billion industry spanning Earth observation, communication and data analytics. We are excited to partner with Archean, whose team brings a wealth of knowledge and a unique partnership approach” said Bogdan Gogulan, CEO and Managing Partner of NewSpace Capital.
NewSpace Capital is a conduit to enable corporates and financial investors to achieve net-zero targets: “The space industry is critical to solving global ESG challenges. In addition to identifying, measuring, and mitigating the environmental impact of existent economic activity that can be done from space on a global scale, space infrastructure and space-enabled services also create a completely new way of operating for traditional industries, that allows the transition to a more efficient and net-zero economy,” said Felix von Schubert, Executive Chairman of NewSpace Capital.
About NewSpace Capital
NewSpace Capital is a global space-focused, growth-stage fund operated by a team that together has more than 150 years of investment, commercial and technical experience in the space and private equity industries. Based in Luxembourg, the fund provides growth capital to companies with a technological edge and leading market position in the supply chain and applications segments of the rapidly developing space ecosystem. To learn more visit www.newspace.capital
About Archean Capital Partners
Archean Capital Partners provides strategic anchor capital to newly-formed private equity firms. Archean was established in 2017 by Veritable, L.P. and Moelis Asset Management to provide initial limited partner capital and value-added support to highly qualified emerging managers. Archean is focused on opportunities in such specialties as buyout, growth, restructuring and turnaround. To learn more visit www.archeancapital.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005797/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom